Valuation: Alvotech

Market Cap 178.46Cr 158.63Cr 147.03Cr 133.77Cr 252.43Cr 17TCr 256.48Cr 1.77TCr 692.93Cr 8.84TCr 669.75Cr 655.49Cr 28TCr P/E 2026 *
96.1x
P/E 2027 * 16.8x
Enterprise Value 286.14Cr 254.35Cr 235.75Cr 214.49Cr 404.76Cr 27TCr 411.25Cr 2.83TCr 1.11TCr 14TCr 1.07TCr 1.05TCr 45TCr EV / Sales 2026 *
4.34x
EV / Sales 2027 * 3.66x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day-3.08%
1 week-1.90%
Current month-2.24%
1 month+11.18%
3 months+68.25%
6 months+56.63%
Current year+10.53%
1 week 4.95
Extreme 4.95
5.89
1 month 4.95
Extreme 4.95
6.53
Current year 2.94
Extreme 2.94
6.53
1 year 2.94
Extreme 2.94
8.74
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 57 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
01/04/26 Free

Chief Executive Officer

1,17,271 0.0355%
01/04/26 Sell

Founder

3,18,000 0.0963%
01/04/26 Buy

Founder

3,18,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
-3.08%-1.90%-35.20%-37.28% 178.46Cr
-6.60%-8.56%+42.79%+64.16% 6.5TCr
-4.09%-0.11%+2.31%+54.81% 5.12TCr
+0.03%+5.56%+10.18%+41.75% 5.12TCr
-1.53%+2.70%+29.72%+34.13% 4.39TCr
-1.34%+4.12%+16.05%+112.18% 4.2TCr
-5.97%-6.22%+258.21%+421.57% 3.81TCr
+6.53%+8.02%+15.74%+53.94% 3.32TCr
-0.90%-10.49%+31.48%-1.63% 2.52TCr
-2.76%-9.54%-16.53%-9.55% 2.2TCr
Average -1.97%-1.10%+35.47%+73.41% 3.74TCr
Weighted average by Cap. -2.30%-1.18%+43.19%+87.98%

Financials

2026 *2027 *
Net sales 66Cr 59Cr 54Cr 49Cr 93Cr 6.26TCr 95Cr 652.95Cr 256.01Cr 3.27TCr 247.44Cr 242.18Cr 10TCr 78Cr 69Cr 64Cr 58Cr 109.72Cr 7.36TCr 111.48Cr 768.19Cr 301.19Cr 3.84TCr 291.11Cr 284.92Cr 12TCr
Net income 3.04Cr 2.7Cr 2.5Cr 2.28Cr 4.29Cr 288.14Cr 4.36Cr 30Cr 12Cr 150.37Cr 11Cr 11Cr 479.34Cr 11Cr 9.7Cr 8.99Cr 8.18Cr 15Cr 1.04TCr 16Cr 108.05Cr 42Cr 540.37Cr 41Cr 40Cr 1.72TCr
Net Debt 107.69Cr 96Cr 89Cr 81Cr 152.33Cr 10TCr 154.77Cr 1.07TCr 418.14Cr 5.33TCr 404.15Cr 395.55Cr 17TCr 105.72Cr 94Cr 87Cr 79Cr 149.54Cr 10TCr 151.93Cr 1.05TCr 410.48Cr 5.24TCr 396.75Cr 388.3Cr 17TCr
Projected Income Statement - Annual - Alvotech
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
16/26/16 $5.000 -5.84% 10,59,087
15/26/15 $5.310 +2.71% 11,56,272
14/26/14 $5.170 -3.90% 10,58,173
13/26/13 $5.380 -2.18% 12,14,031
12/26/12 $5.500 -4.84% 8,41,038
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Alvotech
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.000USD
Average target price
6.800USD
Spread / Average Target
+36.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alvotech
  1. Stock Market
  2. Stocks
  3. ALVO Stock